Protheragen Obesity



CCG 203769

Cat. No.:	OB0225WX-2071
Appearance:	Liquid
Purity:	≥99%
Identity:	Confirmed by NMR, and LC-MS.
Size:	1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 500 mg

This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	CCG 203769 is a selective small molecule inhibitor of RGS4 that disrupts the RGS 4-Gao protein-protein interaction with an IC50 of 17 nM.
Synonym	4-butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione; RGS4 inhibitor 11b; Thiadiazoli dinone (TDZD) deriv. 6; 410074-60-1; CCG 203769; 2-ethyl-4-butyl-1,2,4-thiadiazo lidine-3,5-dione; 4-n-Butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione
CAS No.	410074-60-1
Compound CID	6539137
Formula	$C_8H_{14}N_2O_2S$
Formula Weight	202.27

Specification

Targets&IC50	RGS19: 140 nM; GSK-3β: 5.4 μM; RGS4: 17 nM; RGS8: 79 μM; RGS16: 6 μM
Relative Density	1.179 g/cm^3
IUPAC Name	4-Butyl-2-ethyl-1,2,4-thiadiazolidine-3,5-dione
InChI	InChI=1S/C8H14N2O2S/c1-3-5-6-9-7(11)10(4-2)13-8(9)12/h3-6H2,1-2H3
InChI Key	WTFFYZGCISALRI-UHFFFAOYSA-N
SMILES string	CCCCN1C(=O)N(SC1=O)CC
Stability	3 years in powder form.
Storage	Storage at -20°C.

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com

Protheragen
Obesity



Applications	CCG 203769 is utilized in signal transduction research as a selective RGS4 inhib itor to study the modulation of G-protein coupled receptor signaling and its imp act on dopaminergic pathways.

Library Information

Target	GSK-3; Dopamine receptor; GTPase
Receptor	RGS4; RGS19; RGS16; RGS8; GSK-3β; D2 receptor
Pathways	Stem cells; GPCR/G protein signaling; Neuronal signaling; PI3K/Akt/mTOR signalin g
Plate Number	AOCL-27
Plate Location	e4
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10mM DMSO
DMSO Max Solubility	50 mg/mL; 247.2 mM

Address: 101-4 Colin Dr, Holbrook, NY 11741, USA
Phone: 1-631-506-1393
info@obesityscientific.com